

BIOCON GROUP

FACT SHEET

June - 2026

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 27	Q1 FY 26	Variance %
INCOME			
Biopharmaceuticals			
-Biosimilars	2,855	2,458	16%
-Generics	760	630	21%
Services*	736	875	-16%
Inter-segment revenue	(15)	(21)	28%
Revenue from operations #	4,336	3,942	10%
Other income	55	80	-31%
TOTAL REVENUE	4,391	4,022	9%
EXPENDITURE			
Material & Power costs	1,599	1,514	6%
Staff costs	868	783	11%
Research & Development expenses	240	205	17%
Other expenses	782	675	16%
Manufacturing, staff & other expenses	3,489	3,176	10%
EBITDA	902	846	7%
Interest & Finance charges	213	277	-23%
Depreciation & Amortisation	548	455	20%
PBT BEFORE EXCEPTIONAL ITEM	141	114	24%
Exceptional item, Net	(13)	(17)	
PBT	128	97	32%
Taxes	(6)	12	-150%
Taxes on exceptional item	(3)	(4)	
NET PROFIT BEFORE MINORITY INTEREST	137	89	54%
Minority interest	1	61	-98%
Minority interest on exceptional item	(5)	(3)	
NET PROFIT FOR THE PERIOD	141	31	355%
EPS Rs.	0.9	0.3	
NET PROFIT BEFORE EXCEPTIONAL ITEM	145	42	245%
Exceptional item, net of taxes	(4)	(11)	
NET PROFIT FOR THE PERIOD	141	31	355%
# Licensing Income	10	4	
* Earlier 'CRDMO'			

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 27	Q4 FY 26	Variance %
INCOME			
Biopharmaceuticals			
-Biosimilars	2,855	2,756	4%
-Generics	760	776	-2%
Services*	736	1,037	-29%
Inter-segment revenue	(15)	(52)	71%
Revenue from operations #	4,336	4,517	-4%
Other income	55	53	4%
TOTAL REVENUE	4,391	4,569	-4%
EXPENDITURE			
Material & Power costs	1,599	1,514	6%
Staff costs	868	854	2%
Research & Development expenses	240	277	-13%
Other expenses	782	852	-8%
Manufacturing, staff & other expenses	3,489	3,496	0%
EBITDA	902	1,073	-16%
Interest & Finance charges	213	232	-8%
Depreciation & Amortisation	548	513	7%
PBT BEFORE EXCEPTIONAL ITEM	141	328	-57%
Exceptional item, Net	(13)	(80)	
PBT	128	248	-48%
Taxes	(6)	72	-108%
Taxes on exceptional item	(3)	(23)	
NET PROFIT BEFORE MINORITY INTEREST	137	199	-31%
Minority interest	1	77	-99%
Minority interest on exceptional item	(5)	(4)	
NET PROFIT FOR THE PERIOD	141	126	12%
EPS Rs.	0.9	0.8	
NET PROFIT BEFORE EXCEPTIONAL ITEM	145	179	-19%
Exceptional item, net of taxes	(4)	(53)	
NET PROFIT FOR THE PERIOD	141	126	12%
# Licensing Income	10	3	
* Earlier 'CRDMO'			

BIOCON LIMITED (CONSOLIDATED) BALANCE SHEET		
	(Rs Crores)	
Particulars	Jun 30, 2026	Mar 31, 2026
ASSETS		
Non-current assets		
(a) Property, plant and equipment	9,302	9,473
(b) Capital work-in-progress	4,885	4,613
(c) Right-of-use assets	561	578
(d) Goodwill	18,579	18,377
(e) Other intangible assets	7,917	8,058
(f) Intangible assets under development	2,392	2,374
(g) Financial assets		
Investments	1,620	1,089
Derivative assets	45	43
Other financial assets	420	596
(h) Income tax asset, net	413	429
(i) Deferred tax asset, net	609	556
(j) Other non-current assets	267	285
Non-current assets	47,010	46,471
Current assets		
(a) Inventories	6,733	6,086
(b) Financial assets		
Investments	479	690
Trade receivables	6,827	5,987
Cash and cash equivalents	1,518	2,417
Other bank balances	836	777
Derivative assets	32	22
Other financial assets	247	315
(c) Other current assets	1,014	886
Current assets	17,686	17,180
TOTAL - ASSETS	64,696	63,651
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	815	811
(b) Other equity	34,414	33,221
Equity attributable to owners of the Company	35,229	34,032
Non-controlling interests	2,317	2,590
Total Equity	37,546	36,622
Non-current liabilities		
(a) Financial liabilities		
Borrowings	10,600	10,746
Lease liabilities	521	537
Derivative liabilities	35	68
Other financial liabilities	560	555
(b) Other non-current liabilities	464	481
(c) Provisions	340	330
(d) Deferred tax liability, net	223	243
Non-current liabilities	12,743	12,960
Current liabilities		
(a) Financial liabilities		
Borrowings	4,353	4,078
Lease liabilities	77	72
Trade payables	7,281	6,772
Derivative liabilities	191	248
Other financial liabilities	693	967
(b) Other current liabilities	1,116	1,260
(c) Provisions	215	256
(d) Income tax liability, net	481	416
Current liabilities	14,407	14,069
TOTAL - EQUITY AND LIABILITIES	64,696	63,651